/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of...
Advancement across Company’s pipeline towards regulatory and data milestones...
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...
IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary...
Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier...
Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena’s and VHIO’s leadership in research, translational science, and...
Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development...
Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into...
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed...